body > *:not(noscript) { display: none !important; } noscript { display: block !important; } .no-js-warning { display: flex !important; min-height: 100vh; align-items: center; justify-content: center; padding: 20px; background: #f8f9fa; text-align: center; } .no-js-card { max-width: 500px; padding: 30px; border-radius: 12px; background: white; box-shadow: 0 10px 30px rgba(0,0,0,0.08); font-family: Arial, sans-serif; } .no-js-card h1 { margin-bottom: 10px; }

JavaScript Required

JavaScript is required for this website to work correctly and provide a smooth user experience. Please enable JavaScript in your browser, then refresh the page.

Top story

The Global Pharma Merger and Acquisition Landscape

Read full story

BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation

Pharmaceutical Technology

Wed, 30 Apr 2025

Magazine: The GLP-1 shortage is over. What’s next for compounders?

Pharmaceutical Technology

By Ross Law - Wed, 30 Apr 2025

FDA approves Abeona’s $3.1m cell therapy for rare skin disease

Pharmaceutical Technology

By Jenna Philpott - Wed, 30 Apr 2025

Donald Trump’s first 100 days: Impact on the healthcare industry

Pharmaceutical Technology

By Ross Law - Wed, 30 Apr 2025

Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution

Pharmaceutical Technology

By GlobalData Healthcare - Wed, 30 Apr 2025

AstraZeneca’s Truqap fails in another Phase III trial

Pharmaceutical Technology

By Abigail Beaney - Wed, 30 Apr 2025

Trump’s first 100 days tout US-bound pharma investments amid tariff worries

Pharmaceutical Technology

By Manasi Vaidya - Wed, 30 Apr 2025

Construction begins on MSD’s $1bn biologics centre in Delaware, US

Pharmaceutical Technology

By gullapalli - Wed, 30 Apr 2025

FDA approves AbbVie’s upadacitinib for giant cell arteritis

Pharmaceutical Technology

By gullapalli - Wed, 30 Apr 2025